Sandoz: 9m sales up 6% at CER
(CercleFinance.com) - Sandoz has posted 9m 2023 net sales of $7.
1bn, up 6% at constant exchange rates (+5% in dollars), with volume growth (+9 points) partially offset by price erosion (-3 points).
The Swiss generic and biosimilar drugmaker says that sales growth was mainly driven by Europe, with continued momentum from the previous year's launches and growth in biosimilars.
Sandoz reiterates its financial outlook for FY 2023, with net sales expected to post mid-single digit growth at CER, with a core EBITDA margin expected between 18% and 19%.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
1bn, up 6% at constant exchange rates (+5% in dollars), with volume growth (+9 points) partially offset by price erosion (-3 points).
The Swiss generic and biosimilar drugmaker says that sales growth was mainly driven by Europe, with continued momentum from the previous year's launches and growth in biosimilars.
Sandoz reiterates its financial outlook for FY 2023, with net sales expected to post mid-single digit growth at CER, with a core EBITDA margin expected between 18% and 19%.
Copyright (c) 2023 CercleFinance.com. All rights reserved.